Adaptimmune Therapeutics (ADAP) News Today $0.29 +0.01 (+3.93%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.28 0.00 (-1.01%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Analysts Conflicted on These Healthcare Names: QuidelOrtho (QDEL) and Enliven Therapeutics (ELVN)May 2 at 6:20 PM | theglobeandmail.comAdaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.comStockNews.com began coverage on shares of Adaptimmune Therapeutics in a research report on Wednesday. They set a "buy" rating on the stock.May 2 at 6:33 AM | marketbeat.comTwo Seas Capital LP Takes $7.99 Million Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Two Seas Capital LP acquired a new position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 14,835,146 shares of the biotechnology comApril 27, 2025 | marketbeat.comLong Focus Capital Management LLC Increases Stock Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 54.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,494,393 shares of the biotechnology company's stock afApril 25, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.comStockNews.com began coverage on Adaptimmune Therapeutics in a report on Tuesday. They set a "buy" rating on the stock.April 23, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Given Average Rating of "Moderate Buy" by BrokeragesShares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and foApril 17, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.comStockNews.com began coverage on Adaptimmune Therapeutics in a research report on Monday. They issued a "buy" rating for the company.April 15, 2025 | marketbeat.comAdaptimmune downgraded to Hold from Buy at JonesResearchApril 11, 2025 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Thursday TradingApril 3, 2025 | msn.comWhat Analysts Are Saying About Adaptimmune Therapeutics StockApril 3, 2025 | nasdaq.comHC Wainwright Has Lowered Expectations for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock PriceHC Wainwright dropped their target price on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Tuesday.April 2, 2025 | marketbeat.comAdaptimmune price target lowered to $3 from $3.50 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.com4ADAP : What Analysts Are Saying About Adaptimmune Therapeutics...April 1, 2025 | benzinga.comAdaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.comStockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Saturday. They issued a "buy" rating on the stock.March 30, 2025 | marketbeat.comAnalysts Set Expectations for ADAP Q1 EarningsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Adaptimmune Therapeutics in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Chang anticipates that the biotechnology company will earn ($0.10March 29, 2025 | marketbeat.comBarclays Remains a Sell on Adaptimmune Therapeutics (ADAP)March 28, 2025 | markets.businessinsider.comQ1 Earnings Estimate for ADAP Issued By Zacks Small CapAdaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Zacks Small Cap analyst M. Kim anticipates thatMarch 28, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Given New $1.75 Price Target at GuggenheimGuggenheim dropped their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday.March 27, 2025 | marketbeat.comAdaptimmune price target lowered to $1.75 from $3 at GuggenheimMarch 27, 2025 | markets.businessinsider.comAdaptimmune Therapeutics Amends Loan AgreementMarch 26, 2025 | investing.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comAdaptimmune Therapeutics (ADAP) Gets a Buy from ScotiabankMarch 25, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPSAdaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.March 25, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Recommendation of "Moderate Buy" by AnalystsAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendatiMarch 22, 2025 | marketbeat.comWells Fargo & Company Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50Wells Fargo & Company decreased their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Price Target Lowered to $1.40 at ScotiabankScotiabank dropped their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday.March 22, 2025 | marketbeat.comEarnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025March 22, 2025 | uk.investing.comAdaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | seekingalpha.comAdaptimmune price target lowered to $1.40 from $3.15 at ScotiabankMarch 22, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho SecuritiesMarch 21, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday. They set a "buy" rating for the company.March 21, 2025 | marketbeat.comKSQ Therapeutics Appoints Kristen Hege, M.D., to its Board of DirectorsMarch 5, 2025 | markets.businessinsider.comAdaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge fundsMarch 4, 2025 | finance.yahoo.comAdaptimmune Therapeutics (ADAP) Projected to Post Quarterly Earnings on WednesdayAdaptimmune Therapeutics (NASDAQ:ADAP) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 29.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,819,095 shares of the biotechnoloFebruary 19, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest UpdateAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,880,000 shares, an increase of 19.4% from the January 15th total of 5,760,000 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is presently 3.4 days.February 15, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)February 11, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Crosses Below 50-Day Moving Average - Should You Sell?Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50 Day Moving Average - Here's What HappenedFebruary 11, 2025 | marketbeat.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Significant Increase in Short InterestAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is currently 2.6 days.February 2, 2025 | marketbeat.comGuggenheim Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)January 30, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Below 50-Day Moving Average - Here's What HappenedAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below Fifty Day Moving Average - Time to Sell?January 28, 2025 | marketbeat.comH.C. Wainwright Remains a Buy on Adaptimmune Therapeutics (ADAP)January 23, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years agoJanuary 22, 2025 | uk.finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Increase in Short InterestAdaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 2.6 days.January 19, 2025 | marketbeat.comAdaptimmune therapeutics COO sells shares worth $3,243January 18, 2025 | msn.comAdaptimmune therapeutics' chief medical officer sells $3,243 in stockJanuary 18, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Danaher (DHR)January 14, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)January 12, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Pass Below Fifty Day Moving Average - Here's What HappenedAdaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Passes Below 50-Day Moving Average - What's Next?January 9, 2025 | marketbeat.comPhilly’s year in biopharma: a look back at 2024December 31, 2024 | msn.com Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Media Mentions By Week ADAP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼1.020.73▲Average Medical News Sentiment ADAP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼32▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News ATXS News AQST News AURA News PVLA News ITOS News ACB News CMPX News TSVT News TERN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts